Soligenix, Inc. (SNGX) financial statements (2021 and earlier)

Company profile

Business Address 29 EMMONS DRIVE
PRINCETON, NJ 08540
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments19598956
Cash and cash equivalents19598956
Receivables0111121
Prepaid expense0100000
Deferred costs 0     
Other undisclosed current assets00     
Total current assets:1971091076
Noncurrent Assets
Finance lease, right-of-use asset0 
Property, plant and equipment0000000
Intangible assets, net (including goodwill) 000000
Intangible assets, net (excluding goodwill) 000000
Deposits noncurrent assets0000   
Assets held-in-trust00     
Other noncurrent assets00     
Other undisclosed noncurrent assets000    
Total noncurrent assets:0000000
TOTAL ASSETS:20810101077
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6643353
Accounts payable2322243
Accrued liabilities33211  
Employee-related liabilities1000000
Debt0    0 
Derivative instruments and hedges, liabilities     24
Other undisclosed current liabilities00     
Total current liabilities:6643377
Noncurrent Liabilities
Long-term debt and lease obligation0      
Long-term debt, excluding current maturities0      
Other undisclosed noncurrent liabilities100     
Total noncurrent liabilities:100     
Total liabilities:16643377
Stockholders' equity
Stockholders' equity attributable to parent41667(0)(0)
Common stock0000000
Additional paid in capital197177172164158147139
Accumulated other comprehensive loss(0)(0)(0)    
Accumulated deficit(193)(176)(166)(157)(150)(147)(139)
Total stockholders' equity:41667(0)(0)
TOTAL LIABILITIES AND EQUITY:20810101077

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues25551097
Revenue, net51097
Cost of revenue(2)(4)(5)(4)(8)(7)(5)
Gross profit:1111222
Operating expenses(19)(12)(10)(9)(8)(9)(12)
Operating loss:(19)(11)(9)(8)(6)(7)(11)
Nonoperating income (expense)(0)0002(1)3
Investment income, nonoperating 0002 3
Foreign currency transaction gain (loss), before tax(0)0     
Interest and debt expense(0)(0)     
Other undisclosed income from continuing operations before equity method investments, income taxes00     
Loss from continuing operations before income taxes:(19)(10)(9)(8)(4)(8)(7)
Income tax benefit11 0101
Net loss available to common stockholders, basic:(18)(9)(9)(7)(3)(8)(7)
Other undisclosed net loss available to common stockholders, diluted    (2) (3)
Net loss available to common stockholders, diluted:(18)(9)(9)(7)(5)(8)(10)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(18)(9)(9)(7)(3)(8)(7)
Comprehensive loss:(18)(9)(9)(7)(3)(8)(7)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)(0)    
Comprehensive loss, net of tax, attributable to parent:(18)(9)(9)(7)(3)(8)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: